Finance
Dendreon reports fourth quarter and year-end results, revenue drops
Published in Clinical Oncology Week, April 10th, 2006
Revenues for the year were $210,000, compared to $5.0 million for the year ended December 31, 2004. Revenues for the fourth quarter of 2005 were $37,000, compared to $75,000 for the same period in 2004.
The net loss for the year ended December 31, 2005 was $81.5 million, or $1.36 per share, compared to $75.2 million, or $1.32 per share for the year ended December 31, 2004. Net loss in the fourth quarter of 2005 was $24.8 million, or $0.40 per share, compared to a net loss of $21.7 million, or $0.37 per share, for the same period in 2004. Dendreon's total...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Clinical Oncology Week
More Articles from Clinical Oncology Week
- Bladder Cancer
Nonmuscle invasive micropapillary bladder carcinoma treated by early cystectomy - Lung Cancer
Lung cancer treated by irinotecan and cisplatin - Prostate Cancer
Prostate cancer diagnosed after repeat biopsies linked to favorable prognosis - Radiotherapy
Link between quality of life and fatigue in cancer patients receiving radiotherapy assessed - Soft Tissue Sarcomas
Soft tissue sarcoma should not be treated with gemcitabine as first-line chemotherapy - Acute Myeloid Leukemia
Acute myeloid leukemia outcome not improved after daunorubicin, cytarabine, and thioguanine therapy - More from this issue of Clinical Oncology Week
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
